CN Bio integrates computational modelling with organ-on-chip systems for enhanced drug bioavailability assessment
Cambridge-based CN Bio has expanded its contract research services by integrating PhysioMimix computational modelling tools with existing organ-on-chip platforms, creating a comprehensive approach to absorption, distribution, metabolism and excretion (ADME) profiling for pharmaceutical development.
Enhanced in vitro to in vivo translation capabilities
The new computational tools combine insights from microphysiological system (MPS) assays with mathematical models to provide deeper functional insights into human ADME behaviour. This integration builds upon CN Bio’s proprietary dual-organ gut/liver model, which has been available as both a contract research service and off-the-shelf kit since last year’s bioavailability assay launch.
The enhanced platform addresses critical translation gaps in drug development by generating data compatible with physiologically-based pharmacokinetic (PBPK) frameworks. This compatibility enables extraction of additional insights from preclinical studies whilst providing functional predictions of compound interactions within human biological systems.
Comprehensive support from design to interpretation
CN Bio’s contract research team provides end-to-end collaboration, from ensuring robust experimental design through to translating complex datasets into accessible formats suitable for decision-making processes. The service combines expertise from both MPS specialists and computational modelling scientists to support go/no-go determinations and drug dosing decisions.
“This year, the FDA made significant changes to phase out animal testing requirements, signalling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing. We are providing the tools to ensure our customers stay ahead of these regulatory changes,” said Dr Yassen Abbas, Lead Scientist at CN Bio.
Strategic response to regulatory evolution
Abbas emphasised the service’s role in addressing new regulatory requirements: “The launch of our Bioavailability assay last year was a major step towards improving understanding of the appropriate dose regimens for safe and effective new therapies. Now, by integrating advanced in silico modelling into our offering, we are enhancing this service to bridge the in vitro to in vivo translation gap for drug developers.”
For more information, visit: https://cn-bio.com/in-vitro-services/adme
Digital issue: Please click here for more information
